Author: Takayama, Shin; Kikuchi, Akiko; Makino, Toshiaki; Kainuma, Mosaburo; Namiki, Takao; Ito, Takashi
Title: Basic pharmacological mechanisms and clinical evidence of the efficacy of Hochuekkito against infectious diseases and its potential for use against COVIDâ€19 Cord-id: ji03uh0e Document date: 2020_12_2
ID: ji03uh0e
Snippet: BACKGROUND: Hochuekkito extract (HET) has multiple effects through the digestive and immune systems, including for acute viral infection and chronic inflammation. We review basic pharmacological and clinical researches of HET and discuss the effects of HET against the pandemic COVIDâ€19. METHODS: We reviewed pharmacological studies from 1996 to 30 April 2020 that used experimental animals orally treated with HET and randomized controlled trials (RCTs) from 2000 to 30 April 2020. RESULTS: Altoge
Document: BACKGROUND: Hochuekkito extract (HET) has multiple effects through the digestive and immune systems, including for acute viral infection and chronic inflammation. We review basic pharmacological and clinical researches of HET and discuss the effects of HET against the pandemic COVIDâ€19. METHODS: We reviewed pharmacological studies from 1996 to 30 April 2020 that used experimental animals orally treated with HET and randomized controlled trials (RCTs) from 2000 to 30 April 2020. RESULTS: Altogether, 64 pharmacological studies reported immunoâ€stimulatory effects against infection and cancer, immunoâ€modulative effects against allergy and some inflammatory diseases, and ameliorating effects against exhaustion and frailty. Nine RCTs showed improvement of pulmonary Mycobacterium avium complex disease on chest Xâ€ray; improved systemic inflammation, nutrition, and quality of life of patients with chronic obstructive pulmonary disease and a decrease in the number getting common cold and exacerbations; reduction of soluble interleukinâ€2 receptor and the serum cortisol concentration of postoperative patients; a reduction of the incidence of inflammatory complications and Câ€reactive protein elevation after cerebrovascular disease; a reduction of the volume of steroid and tacrolimus during the treatment of atopic dermatitis; a healing effect for intractable chronic wounds; improvement of the physical status of elderly weak patients; and improvement of the fatigue level of cancer patients. CONCLUSION: CODIVâ€19 is characterized by high risk for the aged and people with other disease complications, cytokine hyperactivity in the severe stage, and sequelae in the recovery stage. Considering the immuneâ€stimulative/modulative effects of HET on inflammatory conditions and against exhaustion and frailty, it may be useful for prevention, treatment, and recovery from COVIDâ€19.
Search related documents:
Co phrase search for related documents- abdominal pain and acute chronic: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- abdominal pain and acute viral infection: 1, 2, 3, 4
- active ingredient and acute viral infection: 1
- acute chronic and additional therapy: 1, 2
Co phrase search for related documents, hyperlinks ordered by date